Program
Adalimumab
Also written as “adalimumab”, “MSB11022” and “M923”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbott | 620 open or running | phase 4since Sep 13, 2005 | Nov 1, 2002 | none ahead |
| AbbVie | 543 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | Sep 2027phase 2 · NCT06257875 |
| Alvotech Swiss | 60 open or running | phase 3since Feb 5, 2019 | Jun 8, 2018 | none ahead |
| Johnson & Johnson | 50 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Fresenius Kabi | 40 open or running | phase 3since Jan 17, 2016 | Jan 17, 2016 | none ahead |
| Biocad | 30 open or running | phase 3since Mar 31, 2016 | Mar 16, 2015 | none ahead |
| Cinnagen | 20 open or running | phase 3since May 24, 2017 | May 24, 2017 | none ahead |
| Sino Biopharmaceutical | 22 open or running | phase 4since Apr 8, 2026 | Apr 8, 2026 | Apr 2028phase 4 · NCT07529925 |
| Takeda | 20 open or running | phase 4since May 5, 2016 | Mar 15, 2015 | none ahead |
| Viatris | 20 open or running | phase 3since Nov 9, 2015 | Jun 3, 2015 | none ahead |
| care-arthritis-ltd | 10 open or running | phase 2since Feb 24, 2015 | Feb 24, 2015 | none ahead |
| Celltrion | 10 open or running | phase 3since Sep 18, 2019 | Sep 18, 2019 | none ahead |
| LG Chem | 10 open or running | phase 1since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| mabscale-llc | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| National Resilience | 10 open or running | phase 3since Jan 10, 2021 | Jan 10, 2021 | none ahead |
| prestige-biopharma-limited | 11 open or running | phase 1since Oct 1, 2021 | Oct 1, 2021 | Jun 2027phase 1 · NCT05108259 |
| Samsung Bioepis | 10 open or running | phase 1since Aug 13, 2020 | Aug 13, 2020 | none ahead |
Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, mylan-gmbh, pharm-olam-llc, ppd-development-lp, pra-health-sciences, ist-gmbh-germany, parexel, pivotal-s-l, GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and abbott-japan-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jun 14, 2012.
- Sep 18, 2019Celltrion's first study: phase 3 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT04171414 · 62 enrolled · Poland
- Dec 10, 2019Phase 3 study in RAAlvotech Swiss · NCT04224194 · 107 enrolled · Georgia, Ukraine
- May 15, 2020Phase 3 study in Plaque PsoriasisAlvotech Swiss · NCT04453137 · 567 enrolled · Georgia, Iceland, Poland and more
- Aug 13, 2020Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT04514796 · 188 enrolled · Germany
- Jan 10, 2021National Resilience's first study: phase 3 study in Mild to Moderate COVID-19New to National ResilienceNational Resilience · NCT04705844
- Oct 1, 2021prestige-biopharma-limited's first study: phase 1 study in Healthy VolunteersNew to prestige-biopharma-limitedprestige-biopharma-limited · NCT05108259 · 160 enrolled · Spain
- Jun 8, 2022Phase 4 study in Non-infectious Intermediate Posterior- or Pan-uveitisAbbVie · NCT05414201 · 87 enrolled · China
- Apr 4, 2023Phase 3 study in Arthritis, RheumatoidAbbVie · NCT05814627 · 487 enrolled · United States, Argentina, Belgium and more
- May 22, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05884242 · 20 enrolled · Belgium
- Jul 5, 2023mabscale-llc's first study: phase 3 study in Plaque PsoriasisNew to mabscale-llcmabscale-llc · NCT06005532 · 494 planned · Russian Federation
- Oct 2, 2023Phase 2 study in Colitis, UlcerativeAbbVie · NCT06257875 · 156 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 3 study in Arthritis, JuvenileAbbVie · NCT06100744 · 40 planned · United States, Australia, Canada and more
- Sep 12, 2025Phase 1 study in Healthy Adult MaleBiocad · NCT07181694 · 444 enrolled · Russia
- Apr 8, 2026Sino Biopharmaceutical's first studies: 2 phase 4 studiesNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT07529925, NCT07564505
Ahead
- Jun 2027Primary completion: phase 1 study in Healthy Volunteersprestige-biopharma-limited · NCT05108259
- Sep 2027Primary completion: phase 2 study in Colitis, UlcerativeAbbVie · NCT06257875
- Apr 2028Primary completion: phase 4 study in Severe Plaque Psoriasis in Chinese ChildrenSino Biopharmaceutical · NCT07529925
- Mar 2029Primary completion: phase 4 study in Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's DiseaseSino Biopharmaceutical · NCT07564505
TargetBeta
“TNF-alpha inhibitor”ChEMBL 37, by rule
Other programs on TNF
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
| CHS-1420rule | nanjing-king-friend-biochemical-pharmaceutical-co-ltd | phase 3 | 2 |
| brivekimig | Sanofi | phase 2 | 6 |
| Hadlimarule | biora-therapeutics-inc | phase 1 | 1 |
Studies
The newest 60 of 149 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07564505Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease · China | 4 | Recruiting | Sino Biopharmaceutical | Mar 2029 | 30 |
| NCT07529925Severe Plaque Psoriasis in Chinese Children | 4 | Not yet recruiting | Sino Biopharmaceutical | Apr 2028 | 30 |
| NCT07181694Healthy Adult Male · Russia | 1 | Completed | Biocad | Feb 12, 2026 | 444 |
| NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more | 3 | Recruiting | AbbVie | Sep 2026 | 40 |
| NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Active, not recruiting | AbbVie | Sep 2027 | 156 |
| NCT06005532Plaque Psoriasis · Russian Federation | 3 | Recruiting | mabscale-llc | Mar 2025 | 494 |
| NCT05884242Healthy · Belgium | 1 | Completed | Johnson & Johnson | Aug 1, 2023 | 20 |
| NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | AbbVie | Jul 15, 2026 | 487 |
| NCT05414201Non-infectious Intermediate Posterior- or Pan-uveitis · China | 4 | Completed | AbbVie | Jun 10, 2024 | 87 |
| NCT05108259Healthy Volunteers · Spain | 1 | Active, not recruiting | prestige-biopharma-limited | Jun 2027 | 160 |
| NCT04705844Mild to Moderate COVID-19 | 3 | Withdrawn | National Resilience | Sep 2022 | 0 |
| NCT04514796Healthy · Germany | 1 | Completed | Samsung Bioepis | May 15, 2021 | 188 |
| NCT04453137Plaque Psoriasis · Georgia, Iceland, Poland and more | 3 | Completed | Alvotech Swiss | May 31, 2021 | 567 |
| NCT04224194RA · Georgia, Ukraine | 3 | Completed | Alvotech Swiss | Jul 8, 2020 | 107 |
| NCT04171414Arthritis, Rheumatoid · Poland | 3 | Completed | Celltrion | Nov 4, 2019 | 62 |
| NCT04018599Arthritis, Rheumatoid · United States | 1 | Completed | Fresenius Kabi | Mar 17, 2020 | 216 |
| NCT03983876Phase 1 · New Zealand | 1 | Completed | Alvotech Swiss | Dec 3, 2019 | 207 |
| NCT03849404Plaque Psoriasis · Estonia, Georgia, Poland and more | 3 | Completed | Alvotech Swiss | Dec 23, 2019 | 413 |
| NCT03849313Healthy Volunteers · Australia, New Zealand | 1 | Completed | Alvotech Swiss | Feb 17, 2020 | 390 |
| NCT03823391Arthritis, Rheumatoid · United States, Germany, Hungary and more | 2 | Completed | AbbVie | Apr 8, 2020 | 48 |
| NCT03579823Healthy Volunteers · Australia | 1 | Completed | Alvotech Swiss | Aug 24, 2018 | 24 |
| NCT03311464Pyoderma Gangrenosum · Japan | 3 | Completed | AbbVie | Aug 20, 2019 | 22 |
| NCT03273192Bioequivalence · Iran, Islamic Republic of | 1 | Completed | Cinnagen | Aug 6, 2017 | 74 |
| NCT03172325Active Rheumatoid Arthritis · Iran, Islamic Republic of | 3 | Completed | Cinnagen | Aug 17, 2016 | 136 |
| NCT03052322Moderate to Severe Rheumatoid Arthritis · Bulgaria, Czechia, Germany and more | 3 | Completed | Fresenius Kabi | May 28, 2018 | 288 |
| NCT03014947Healthy Subjects | 1 | Completed | Fresenius Kabi | Dec 2014 | 237 |
| NCT02904902Hidradenitis Suppurativa · Japan | 3 | Completed | AbbVie | Sep 1, 2017 | 15 |
| NCT02897115Axial Spondyloarthritis | 4 | Terminated | AbbVie | Dec 21, 2017 | 22 |
| NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more | 4 | Completed | AbbVie | Sep 23, 2019 | 246 |
| NCT02808975Hidradenitis Suppurativa · United States, Belgium, Canada and more | 4 | Completed | AbbVie | May 16, 2019 | 206 |
| NCT02764762Crohn Disease · United States, Canada | 4 | Completed | Takeda | Sep 22, 2020 | 55 |
| NCT02762955Psoriasis · Russian Federation | 3 | Completed | Biocad | Dec 2017 | 344 |
| NCT02722044Arthritis, Rheumatoid · United States | 3 | Completed | Johnson & Johnson | Feb 21, 2017 | 33 |
| NCT02675023Healthy · United States, United Kingdom | 1 | Completed | Johnson & Johnson | Jul 2016 | 603 |
| NCT02660580Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Fresenius Kabi | Dec 31, 2016 | 443 |
| NCT02632175Colitis, Ulcerative · United States, Japan, Poland and more | 3 | Completed | AbbVie | Apr 8, 2025 | 59 |
| NCT02629159Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Oct 27, 2017 | 1,629 |
| NCT02714322Psoriasis · Bulgaria, Estonia, Hungary and more | 3 | Completed | Viatris | May 2016 | 294 |
| NCT02581345Psoriasis · United States, Bulgaria, Canada and more | 3 | Completed | Johnson & Johnson | Apr 4, 2017 | 572 |
| NCT02533375Psoriasis | 3 | Completed | AbbVie | Sep 15, 2016 | 10 |
| NCT02499783Crohn Disease | 3 | Completed | AbbVie | May 19, 2017 | 205 |
| NCT02472912Healthy Volunteers · Belgium | 1 | Completed | Viatris | May 2015 | 270 |
| NCT02395055Healthy · Russian Federation | 1 | Completed | Biocad | Oct 2015 | 94 |
| NCT02393378Arthritis, Rheumatoid · Czechia, Estonia, Russian Federation and more | 2 | Terminated | Takeda | Jun 27, 2016 | 7 |
| NCT02471118Osteoarthritis, Knee · Canada | 2 | Completed | care-arthritis-ltd | Mar 2021 | 62 |
| NCT02206867Healthy Subjects | 1 | Completed | LG Chem | Feb 2015 | 116 |
| NCT02198651Arthritis, Rheumatoid · United States, Australia, Austria and more | 4 | Completed | AbbVie | May 3, 2018 | 149 |
| NCT02196701Psoriasis | 3 | Completed | AbbVie | Mar 17, 2017 | 46 |
| NCT02185014Crohn Disease | 3 | Completed | AbbVie | Nov 3, 2017 | 252 |
| NCT02148718Crohn Disease | 4 | Completed | AbbVie | Aug 2016 | 100 |
| NCT02065622Colitis, Ulcerative · United States, Austria, Belgium and more | 3 | Completed | AbbVie | Sep 5, 2019 | 952 |
| NCT02065570Crohn Disease · United States, Austria, Belgium and more | 3 | Completed | AbbVie | Jan 30, 2020 | 514 |
| NCT02065557Colitis, Ulcerative · United States, Australia, Austria and more | 3 | Completed | AbbVie | Feb 7, 2020 | 101 |
| NCT02019472Arthritis, Rheumatoid · United States, Bulgaria, Chile and more | 3 | Completed | Johnson & Johnson | Aug 17, 2016 | 559 |
| NCT02016482Nail Psoriasis | 3 | Completed | AbbVie | Oct 2015 | 217 |
| NCT02015793Crohn Disease | 2 | Completed | AbbVie | Feb 2015 | 30 |
| NCT01958827Crohn Disease | 3 | Completed | AbbVie | Mar 2015 | 28 |
| NCT01808118Axial Spondyloarthritis | 3 | Completed | AbbVie | Feb 21, 2017 | 673 |
| NCT01752855Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more | 2 | Completed | AbbVie | Oct 2013 | 88 |
| NCT01712178Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more | 2 | Completed | AbbVie | May 2013 | 100 |
How it is read
Names in the registry
- “Adalimumab”, 69 entries
- “adalimumab”, 63 entries
- “MSB11022”, 3 entries
- “M923”, 3 entries
- “Humira (adalimumab)”, 3 entries
Codes read as this program: AVT02.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 45 studies
- Psoriasis, 25 studies
- Crohn Disease, 23 studies
- Colitis, Ulcerative, 9 studies
- Hidradenitis Suppurativa, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.